Navigation Links
AnazaoHealth Announces Full Continued Cooperation with FDA to Promote Quality Assurance and Patient Safety
Date:3/8/2013

TAMPA, Fla., March 8, 2013 /PRNewswire/ -- Staying true to its commitment to patient safety, specialty pharmacy AnazaoHealth Corporation has announced continued investment in quality assurance measures, including full cooperation with the U.S. Food and Drug Administration (FDA) to assess and improve quality practices. The specialty pharmacy has been in the compounding pharmacy business for more than 15 years, and more than 95 percent of its business remains patient-specific.  Because it does not mass-produce medications and fills patient-specific prescriptions from licensed physicians, the pharmacy is not regulated by FDA Manufacturing Guidelines – instead adhering to USP<797> standards developed specifically for the compounding pharmacy industry and adopted into law by the Florida Board of Pharmacy.  Despite this, AnazaoHealth is fully cooperating with the FDA, who inspected AnazaoHealth alongside state agency inspectors who found no deficiencies.  The pharmacy continues to seek other internal and external audits to ensure the highest standards of quality and patient safety. 

"While the debate is being waged on what standards are most appropriate for the compounding pharmacy industry, we remain focused on promoting quality assurance of the highest standard, no matter what," said Jacob J. Beckel , chairman and CEO, AnazaoHealth.  "That is why in addition to meeting or exceeding all standards of our regulating body -- the Florida Board of Pharmacy -- we are also implementing measures above-and-beyond, including actions based on some of the observations by the FDA."

Throughout its history, AnazaoHealth has regularly sought both internal and external audits performed by industry experts to evaluate and guide its industry-leading quality assurance program, helping the company to meet and / or exceed all USP <797> sterile compounding and USP <795> non-sterile compounding standards.  AnazaoHealth was among the first in the country to be awarded accreditation from the Pharmacy Compounding Accreditation Board (PCAB) in 2008, and remains accredited today. Pharmacists serve as Corporate Quality Director, Corporate Quality Manager, and as divisional Clinical Quality Managers.  The company's sterile compounding process involves no fewer than four different validation checks prior to completion of an order and makes extensive use of bar code technology, lessening chance of human error.  AnazaoHealth is also planning further investment in enhancing its level of sterility testing, addressing some of the recommendations made during the recent FDA inspection.

"We know how important this is – this is the safety of our patients, and patient care is at the heart of our pharmacy," said David Joseph , R.Ph, director of pharmacy, quality and regulatory compliance, AnazaoHealth. "We are proud of our quality program, and we will continue to make improvements to uphold the highest standards in the pharmacy industry."

About AnazaoHealth
AnazaoHealth Corporation, a specialty pharmacy, has been in the compounding pharmacy business for over fifteen years, focusing on patient specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials.  More information is available at www.anazaohealth.com


'/>"/>
SOURCE AnazaoHealth Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
2. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
3. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of Compliance by NYSE MKT LLC
6. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
7. MiMedx Announces 2012 Results
8. CCS Medical Announces Agreement with LifeScan
9. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
10. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
(Date:5/10/2017)... 2017  The Corporate Whistleblower Center says, "We ... therapy clinics to call us anytime at 866-714-6466 if ... involved in a substantial scheme to overbill Medicare. ... an employee of a medical equipment company if ... provide medical practice groups with extra generous incentives to ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability ... Policy Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price ... Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the ... month as a Guest Speaker and Contributor to a weeklong series of classes, meetings, ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... educating patients on peri-implantitis in Las Vegas, NV, and the importance ... custom gum disease consultation and leading care for peri-implantitis, with or without a ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients from Charleston, SC, are now welcome to ... Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction can transform ... teeth in Charleston, SC. Those who suffer from gum disease, misaligned teeth or ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients looking for an alternative ... or without a referral, from the multi-specialty Dr. Smile practice. Dr. Esther Feldman ... in providing patients with the custom, convenient and long-lasting orthodontic treatment that helps ...
Breaking Medicine News(10 mins):